Clinical Trials in New York
Browse 100 New York Medical Studies Across 789 Cities
42 Phase 3 Trial · 3637 New York Clinics
Reviewed by Michael Gill, B. Sc.
Efzofitimod 3 Mg/kgfor Sarcoidosis
18 - 75
This trial is testing two different doses of a new drug, efzofitimod, to see if it can improve symptoms and lung function in people with pulmonary sarcoidosis.
aTyr Investigative Site (+38 Sites)Lisa CareyaTyr Pharma, Inc.
Posoleucel (ALVR105)for Adenovirus Infections
This trial will test an allogeneic, multi-virus specific T cell therapy for six viral pathogens.
Phase 2 & 3
University of Alabama at Birmingham (+49 Sites)AlloVir
ZN-c3for Ovarian Cancer
This trial is testing a new combination drug treatment for women with ovarian cancer that has stopped responding to other treatments.
Phase 1 & 2
Site 0136 (+25 Sites)K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Osimertinibfor Non-Small Cell Lung Cancer
This trial will study whether osimertinib can prevent recurrence of EGFRm non-small cell lung cancer in people who have had surgery to remove the tumor.
Research Site (+14 Sites)Jonathan Goldman, MDAstraZeneca
Three MDMA-assisted Psychotherapy Sessionsfor Post-Traumatic Stress Disorder
This trial will compare the effectiveness of 2 vs 3 sessions of MDMA-assisted therapy in treating PTSD in US military veterans.
James J. Peters VA Medical CenterRachel Yehuda
Pembrolizumabfor Oral Cancers
18 - 79
This trial is testing pembrolizumab, a monoclonal antibody, in combination with radiation therapy or pembrolizumab alone compared to the usual approach of chemotherapy plus radiation therapy after surgery in treating patients with head and neck squamous cell carcinoma that has come back or patients with a second head and neck cancer that is not from metastasis.
University of Florida Health Science Center - Gainesville (+99 Sites)Dan P Zandberg
Tipifarnibfor Wilms Tumor
12 - 21
This trial studies how well tipifarnib works in treating patients with advanced solid tumors, lymphoma, or histiocytic disorders that have a HRAS gene alteration.
Children's Hospital of Alabama (+99 Sites)Christine A Pratilas
Autologous Hematopoietic Stem Cell Transplantationfor Mantle Cell Lymphoma
18 - 70
This trial is testing if rituximab works better with or without stem cell transplant for mantle cell lymphoma in patients who are in first complete remission.
University of Alabama at Birmingham Cancer Center (+99 Sites)Timothy Fenske
Certolizumab Pegol (CZP)for Juvenile Idiopathic Arthritis
2 - 17
Washington, United States
This trial looks at the effects of a drug called certolizumab pegol in children and adolescents with a type of arthritis called juvenile idiopathic arthritis.
Ra0043 081 (+22 Sites)UCB CaresUCB BIOSCIENCES GmbH
Oxybutyninfor Overactive Bladder
3 - 16
Loma Linda, CA
This trial will study the safety and effectiveness of a gel form of the drug oxybutynin in children 3-17 years old with overactive bladder due to a neurological condition.
Loma Linda University Health (+15 Sites)Anna ChanAllergan
10 New York Clinical Trials Near Me
Top Cities for New York Clinical TrialsNew York Clinical Trials by Phase of Trial
N/A New York Clinical TrialsMost Recent New York Clinical Trials
10Active New York Clinical Trials
10Number of Unique Treatments
143Number of Active Locations
Began Recruiting Date
Phase 2 & 3
References1 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/314019032 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. https://pubmed.ncbi.nlm.nih.gov/314019033 Mellon L, Doyle F, Hickey A, Ward KD, de Freitas DG, McCormick PA, O'Connell O, Conlon P. Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients. Cochrane Database Syst Rev. 2022 Sep 12;9:CD012854. doi: 10.1002/14651858.CD012854.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/360948294 Mellon L, Doyle F, Hickey A, Ward KD, de Freitas DG, McCormick PA, O'Connell O, Conlon P. Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients. Cochrane Database Syst Rev. 2022 Sep 12;9(9):CD012854. doi: 10.1002/14651858.CD012854.pub2. https://pubmed.ncbi.nlm.nih.gov/360948295 Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68. doi: 10.1183/09031936.05.00035205. No abstract available. https://pubmed.ncbi.nlm.nih.gov/162640586 Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7. https://pubmed.ncbi.nlm.nih.gov/287834527 Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T 3rd, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):246-256.e2. doi: 10.1016/j.clml.2020.11.005. Epub 2020 Nov 11. https://pubmed.ncbi.nlm.nih.gov/332884858 Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. J Urol. 2009 Oct;182(4):1548-54. doi: 10.1016/j.juro.2009.06.058. Epub 2009 Aug 15. Erratum in: J Urol. 2009 Dec;182(6):2985. Dosage error in article text. https://pubmed.ncbi.nlm.nih.gov/196837319 McDougall CG, Spetzler RF, Zabramski JM, Partovi S, Hills NK, Nakaji P, Albuquerque FC. The Barrow Ruptured Aneurysm Trial. J Neurosurg. 2012 Jan;116(1):135-44. doi: 10.3171/2011.8.JNS101767. Epub 2011 Nov 4. https://pubmed.ncbi.nlm.nih.gov/2205421310 Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008 Nov 27;359(22):2355-65. doi: 10.1056/NEJMra0800353. No abstract available. https://pubmed.ncbi.nlm.nih.gov/19038881